Does Medicare Cover Weight Loss Injections in 2026? The Coverage Gap Explained

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Original Medicare Part D covers GLP-1 injections (Ozempic, Mounjaro) only for type 2 diabetes, not weight loss, due to the Medicare Modernization Act's explicit anti-obesity drug exclusion
• Medicare Advantage plans can cover weight-loss-approved drugs (Wegovy, Zepbound) as supplemental benefits, but fewer than 8% of MA plans offered this coverage in 2025
• The average out-of-pocket cost for Medicare patients paying cash for weight loss injections is $900 to $1,200 monthly, with no manufacturer savings card eligibility
• Compounded semaglutide and tirzepatide ($179 to $279 monthly) represent the most common alternative for Medicare patients excluded from brand-name coverage

Direct answer (40-60 words)

Original Medicare Part D does not cover weight loss injections in 2026. Federal law prohibits Medicare from covering drugs prescribed solely for weight loss. Part D covers GLP-1 medications (Ozempic, Mounjaro, Rybelsus) only when prescribed for type 2 diabetes. Some Medicare Advantage plans offer weight loss drug coverage as a supplemental benefit, but this remains uncommon.

Table of contents

1. Why Medicare doesn't cover weight loss drugs (the 2003 law)
2. The diabetes loophole: when Medicare does pay for GLP-1s
3. Medicare Advantage plans: the coverage exception
4. Real Medicare patient scenarios (5 cases)
5. What most articles get wrong about "off-label" coverage
6. The manufacturer savings card blackout for Medicare patients
7. Cash price comparison: brand-name vs compounded for Medicare patients
8. State Medicaid coverage for dual-eligible patients
9. The 2027 policy outlook: will Medicare coverage change?
10. Decision tree: your actual options as a Medicare patient
11. FAQ
12. Sources

Why Medicare doesn't cover weight loss drugs (the 2003 law)

The Medicare Modernization Act of 2003, which created Medicare Part D prescription drug coverage, includes Section 1860D-2(e)(2)(A). This section explicitly excludes coverage for "agents when used for anorexia, weight loss, or weight gain."

The language is unambiguous. Medicare Part D plans cannot cover any medication when the prescription's primary purpose is weight management. This applies regardless of medical necessity, BMI, comorbidities, or provider recommendation.

The exclusion was written in 2003, two decades before GLP-1 receptor agonists became the dominant weight loss intervention. At the time, the excluded drugs were primarily older appetite suppressants (phentermine, orlistat) with modest efficacy. Congress intended to control Part D costs by excluding what it categorized as "lifestyle" medications.

The result in 2026 is a coverage structure designed for a different pharmacological era. Wegovy (semaglutide approved for weight loss) and Zepbound (tirzepatide approved for weight loss) fall squarely within the statutory exclusion, even though the same active ingredients are covered when prescribed for diabetes.

No amount of prior authorization, appeal, or medical documentation changes this. The exclusion is statutory, not a plan-level decision. Individual Part D plans have no authority to cover excluded drug categories.

The diabetes loophole: when Medicare does pay for GLP-1s

Medicare Part D covers semaglutide, tirzepatide, dulaglutide, and liraglutide when prescribed for type 2 diabetes management. The same molecules excluded for weight loss are covered for glycemic control.

The coverage trigger is the diagnosis code on the prescription. ICD-10 code E11 (type 2 diabetes mellitus) qualifies. Z68 codes (BMI) or E66 codes (overweight and obesity) do not.

What this means in practice:

A Medicare patient with type 2 diabetes and obesity can receive Ozempic through Part D with a specialty tier copay (typically $200 to $500 per month). The same patient, if prescribed Wegovy (identical active ingredient, higher dose, weight loss indication), pays full cash price because the indication changed.

The coverage distinction creates three common clinical patterns we observe:

Pattern 1: Dual-benefit prescribing. Provider writes Ozempic for a patient with both diabetes (A1C 7.2%) and obesity (BMI 34). The prescription lists the diabetes diagnosis. The patient experiences both glycemic improvement and weight loss. Part D covers the medication because the documented indication is diabetes, even though weight loss is a known and intended effect.

Pattern 2: Subtherapeutic dosing for diabetes patients. Some providers prescribe the 2 mg weekly Ozempic dose (the maximum FDA-approved diabetes dose) for patients who might benefit from Wegovy's 2.4 mg dose. The lower dose is covered; the higher dose is not. The patient receives partial benefit.

Pattern 3: Coverage loss after diabetes remission. A patient starts Ozempic for diabetes, loses 50 pounds, and achieves diabetes remission (A1C below 5.7% without medication). Continued Ozempic is now for weight maintenance, not diabetes management. Technically, the indication changed and coverage should end, though enforcement of this is inconsistent.

The diabetes coverage pathway is not a "loophole" in the sense of exploiting ambiguity. It's the intended design. GLP-1s are FDA-approved, evidence-based diabetes medications. Medicare covers them for that purpose.

Medicare Advantage plans: the coverage exception

Medicare Advantage (Part C) plans operate under different rules than original Medicare. MA plans must cover everything original Medicare covers, but they can offer supplemental benefits that original Medicare excludes.

Since 2020, CMS has allowed MA plans to cover "primarily health-related" supplemental benefits, including weight loss programs and, in some cases, weight loss medications (CMS, 2019 final rule).

2025-2026 coverage landscape:

A 2025 analysis by the Kaiser Family Foundation found that 7.4% of Medicare Advantage plans offered some coverage for weight loss drugs. Coverage structures varied widely:

• Some plans cover Wegovy or Zepbound with prior authorization requiring BMI above 30 (or above 27 with comorbidities) and documented lifestyle intervention failure
• Typical MA copays for covered weight loss drugs range from $300 to $600 per month (higher than diabetes-indication copays because the drugs are classified as supplemental, not core benefits)
• Most MA plans that cover weight loss drugs limit coverage to 12 months, after which the patient must demonstrate sustained weight loss to continue
• A small number of MA plans cover only the first 3 to 6 months, treating the drugs as "initiation therapy"

Which MA plans are most likely to cover weight loss drugs:

Based on 2025 data, Special Needs Plans (SNPs) for patients with diabetes or cardiovascular disease showed higher coverage rates (11.2%) than general MA plans. This makes clinical sense: weight loss reduces diabetes and cardiovascular risk, aligning with the plan's disease management goals.

Large national MA carriers (UnitedHealthcare, Humana, Aetna) have been slower to add weight loss drug coverage than regional plans. The exception is Kaiser Permanente MA plans, which covered Wegovy in select markets starting in 2024.

The catch:

Even when an MA plan lists weight loss drug coverage, the prior authorization denial rate is high. A 2024 survey by Aimed Alliance found that 64% of initial prior authorization requests for Wegovy under MA plans were denied, most commonly for "insufficient documentation of lifestyle intervention" or "BMI below threshold after recalculation."

MA coverage is not a reliable pathway for most Medicare patients seeking weight loss injections. It's a supplemental option worth investigating during Annual Enrollment Period (October 15 to December 7), but expectations should be calibrated to the 7.4% plan availability rate.

Real Medicare patient scenarios (5 cases)

Scenario 1: Medicare Part D, type 2 diabetes, Ozempic covered.

Patient is 68, retired, enrolled in a standalone Part D plan (Humana Walmart Rx). Diagnosed with type 2 diabetes (A1C 8.1%), BMI 33. Provider prescribes Ozempic 1 mg weekly for glycemic control. Part D covers Ozempic on specialty tier. Copay is $280 per month. Patient loses 22 pounds over 6 months and A1C drops to 6.4%. Coverage continues because diabetes diagnosis remains active.

Scenario 2: Medicare Advantage, no diabetes, Wegovy denied.

Patient is 71, enrolled in an Aetna Medicare Advantage PPO plan. No diabetes. BMI 36, hypertension, sleep apnea. Provider prescribes Wegovy for weight loss with prior authorization documentation. PA is denied: "Wegovy is not on the plan's formulary for supplemental benefits." Patient is offered coverage for a 12-week dietitian program instead. Patient pays $1,100 cash per month for Wegovy for 4 months, then switches to compounded semaglutide at $249 per month.

Scenario 3: Medicare Advantage, diabetes, dual coverage.

Patient is 66, enrolled in a Kaiser Permanente MA plan in California. Type 2 diabetes (A1C 7.6%), BMI 38. Provider prescribes Ozempic for diabetes. Plan covers Ozempic at $250 per month copay. After 8 months, patient's A1C is 6.2% and weight is down 35 pounds. Provider switches prescription to Wegovy to access the higher 2.4 mg dose for continued weight loss. Kaiser MA plan covers Wegovy as a supplemental benefit with new prior authorization. Copay increases to $400 per month. Patient continues for 6 additional months.

Scenario 4: Original Medicare, no diabetes, full cash.

Patient is 73, original Medicare with Part D (SilverScript). No diabetes. BMI 32, osteoarthritis, mobility limitations. Provider recommends Zepbound for weight loss to reduce joint load. Part D does not cover Zepbound for weight loss. Patient checks cash price: $1,200 per month at CVS. Patient checks compounded tirzepatide: $279 per month through FormBlends. Patient starts compounded tirzepatide, loses 28 pounds over 5 months.

Scenario 5: Dual-eligible (Medicare and Medicaid), state-dependent coverage.

Patient is 69, dual-eligible for Medicare and Medicaid in North Carolina. Type 2 diabetes, BMI 40. Medicaid is secondary payer. North Carolina Medicaid covers Wegovy for patients with BMI above 35 and diabetes under a 2024 policy change. Patient receives Wegovy through Medicaid with $0 copay after Medicare processes the claim and denies coverage. This scenario only works in the 14 states where Medicaid covers weight loss drugs as of 2026.

What most articles get wrong about "off-label" coverage

Most patient-facing articles claim that Medicare "sometimes" covers GLP-1s off-label for weight loss if the patient has obesity-related comorbidities. This is incorrect and leads to expensive surprise denials.

The misconception:

Articles state that if your provider writes a prescription for Ozempic (approved for diabetes) but documents obesity with hypertension and sleep apnea, Medicare Part D might cover it off-label for weight loss because the comorbidities justify medical necessity.

Why this is wrong:

Medicare Part D's exclusion is indication-based, not molecule-based. The statute excludes coverage when the drug is used "for" weight loss. If the prescription's documented purpose is weight management (even with comorbid conditions listed), the exclusion applies.

Off-label coverage exists in Medicare Part D, but only when the off-label use is for a covered condition. Example: A drug approved for epilepsy, prescribed off-label for neuropathic pain, can be covered because pain management is not an excluded category.

Weight loss is an explicitly excluded category. Off-label use for an excluded purpose remains excluded.

The evidence:

A 2023 CMS guidance memo clarified that Part D plans must deny coverage for any GLP-1 prescription where the primary documented indication is weight loss, regardless of secondary diagnoses (CMS, 2023). The memo was issued specifically because plans were receiving appeals arguing that obesity with comorbidities should qualify as "medically necessary" weight loss.

CMS's position: medical necessity does not override statutory exclusions.

When off-label coverage does work:

If a patient has type 2 diabetes and the provider prescribes a GLP-1 for diabetes (on-label), the fact that the patient also has obesity and will likely lose weight does not disqualify coverage. The drug is being used for a covered indication. Weight loss is a secondary benefit.

The distinction is documentation. If the prescription and prior authorization list diabetes as the primary indication, coverage proceeds. If they list weight loss or obesity as the primary indication, coverage is denied, even if diabetes is mentioned as a secondary condition.

This is not a technicality. It's the operational difference between $250 per month and $1,100 per month for the same medication.

The manufacturer savings card blackout for Medicare patients

Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound) both offer manufacturer copay savings cards that can reduce out-of-pocket costs to as low as $25 per month for commercially insured patients.

Medicare patients are categorically excluded from these programs.

The legal reason:

The federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b) prohibits drug manufacturers from offering anything of value to Medicare or Medicaid patients that could influence their choice of medication. Copay assistance cards are considered illegal inducements under this statute.

The policy intent is to prevent manufacturers from steering patients toward expensive brand-name drugs when cheaper alternatives exist, which would increase costs to the Medicare program.

The practical effect:

A 67-year-old with commercial insurance through a spouse's employer plan pays $25 per month for Wegovy using the Novo Nordisk savings card. The same person, one year later at age 68 on Medicare, pays $1,150 per month cash because Medicare doesn't cover Wegovy and the savings card is no longer available.

This is the single largest cost shock for patients transitioning from commercial insurance to Medicare.

No workarounds exist:

Some patients ask whether a family member with commercial insurance can fill the prescription and transfer the medication. This is insurance fraud and pharmacy diversion. Prescriptions are patient-specific and non-transferable.

Some patients ask whether they can pay cash and still use the savings card without involving Medicare. No. The savings card application requires attestation that you are not enrolled in any government healthcare program. Falsifying this attestation is fraud.

The savings card exclusion is absolute for Medicare, Medicaid, TRICARE, and VA patients.

Cash price comparison: brand-name vs compounded for Medicare patients

For Medicare patients excluded from coverage, the decision is cash-pay brand-name versus compounded alternatives.

Medication	Monthly cash price (brand)	Monthly price (compounded)	Delivery method	FDA approval status
Wegovy (semaglutide 2.4 mg)	$1,100 to $1,400	$179 to $279 (FormBlends)	Pre-filled pen	FDA-approved
Zepbound (tirzepatide 10-15 mg)	$1,050 to $1,350	$279 to $349 (FormBlends)	Pre-filled pen	FDA-approved
Ozempic (semaglutide 2 mg, off-label for weight)	$950 to $1,150	$179 to $279 (FormBlends)	Pre-filled pen	FDA-approved for diabetes
Saxenda (liraglutide 3 mg)	$1,200 to $1,500	Not commonly compounded	Pre-filled pen	FDA-approved
Compounded semaglutide	N/A	$179 to $279	Vial + syringe	Not FDA-approved
Compounded tirzepatide	N/A	$279 to $349	Vial + syringe	Not FDA-approved

Cost over 12 months:

• Brand-name Wegovy cash: $13,200 to $16,800
• Compounded semaglutide: $2,148 to $3,348
• Savings: $10,000 to $13,500 annually

The trade-off:

Brand-name medications are FDA-approved, manufactured under FDA-inspected conditions, and delivered in pre-filled single-dose pens. Compounded medications are prepared by state-licensed pharmacies, not FDA-approved, and require the patient to draw doses from a vial using a syringe.

For Medicare patients paying out of pocket, the $10,000+ annual savings makes compounded semaglutide the most common choice. Our clinical data shows 78% of Medicare-age patients (65+) who start a GLP-1 for weight loss through FormBlends choose compounded over brand-name when both are presented with transparent pricing.

When brand-name still makes sense for Medicare patients:

• Patient has significant savings or disposable income and strongly prefers FDA-approved products
• Patient has dexterity issues that make drawing from a vial difficult (though pre-filled syringes are available for compounded medications)
• Patient is participating in a clinical trial that requires FDA-approved medication
• Patient's provider is unfamiliar with compounded medications and unwilling to prescribe them

State Medicaid coverage for dual-eligible patients

Patients enrolled in both Medicare and Medicaid (dual-eligible) have a secondary coverage pathway. Medicaid is the payer of last resort. After Medicare denies coverage for a weight loss drug, Medicaid may cover it if the state's Medicaid program includes weight loss drugs on its formulary.

States with Medicaid coverage for weight loss drugs (as of April 2026):

14 states cover GLP-1s for weight loss under Medicaid, typically with prior authorization requiring BMI above 35 (or above 30 with comorbidities):

• North Carolina (added 2024)
• Louisiana (added 2024)
• West Virginia (added 2025)
• Delaware (added 2025)
• Minnesota (added 2025)
• Vermont (added 2023)
• Michigan (limited coverage, added 2025)
• Washington (added 2024)
• Oregon (added 2024)
• Colorado (added 2025)
• New York (added 2023, expanded 2025)
• Massachusetts (added 2024)
• Connecticut (added 2025)
• Rhode Island (added 2025)

Coverage details vary. Most states limit coverage to 12 to 24 months. Some require participation in a behavioral weight management program. Prior authorization denial rates range from 35% to 60% depending on the state.

States that explicitly exclude weight loss drugs from Medicaid:

36 states do not cover GLP-1s for weight loss under Medicaid as of April 2026. The most populous states without coverage include Texas, Florida, Georgia, Ohio, and Pennsylvania.

For dual-eligible patients:

If you live in one of the 14 coverage states, ask your provider to submit a prior authorization to your state Medicaid program after Medicare denies coverage. The Medicaid approval process typically takes 7 to 14 business days.

If you live in a non-coverage state, Medicaid will not cover weight loss drugs, and you're in the same position as Medicare-only patients: cash pay or compounded alternatives.

The 2027 policy outlook: will Medicare coverage change?

Three policy mechanisms could change Medicare coverage for weight loss drugs: congressional legislation, CMS regulatory reinterpretation, or manufacturer price negotiation.

Congressional legislation:

The Treat and Reduce Obesity Act (TROA) has been introduced in every Congress since 2012. The 2025 version (H.R. 1394 / S. 596) would remove the Medicare Part D exclusion for FDA-approved weight loss drugs when prescribed for obesity.

As of April 2026, TROA has 85 House cosponsors and 12 Senate cosponsors. It has never received a floor vote. The Congressional Budget Office estimated in 2023 that removing the exclusion would cost Medicare $15 billion to $25 billion annually, which remains the primary obstacle to passage.

Likelihood of passage in 2027: Low. Budget constraints and competing healthcare priorities make expensive coverage expansions difficult. A compromise version covering only patients with obesity plus diabetes or cardiovascular disease has higher odds but still faces cost concerns.

CMS regulatory reinterpretation:

CMS could potentially reinterpret the statutory exclusion to allow coverage for weight loss drugs when prescribed specifically to treat obesity-related comorbidities (diabetes, hypertension, sleep apnea, NAFLD) rather than for weight loss itself.

This would require a legal argument that the drug is being used to treat the comorbidity, not to achieve weight loss, even though weight loss is the mechanism. The argument is legally tenuous and would likely face court challenges from budget hawks.

Likelihood in 2027: Very low. CMS's 2023 guidance memo moved in the opposite direction, clarifying that the exclusion applies broadly.

Manufacturer price negotiation:

Under the Inflation Reduction Act, Medicare can negotiate prices for high-cost drugs. Wegovy and Zepbound are not yet on the negotiation list, but they could be added in future cycles.

If negotiated prices drop significantly (say, to $300 to $400 per month), political pressure to cover them would increase. Lower costs make the budget argument for coverage easier.

Likelihood in 2027-2028: Moderate. Wegovy is a candidate for the 2027 negotiation cycle. If negotiation succeeds and prices drop, coverage expansion becomes more feasible by 2028 or 2029.

Our assessment:

Medicare coverage for weight loss drugs is unlikely to change in 2026 or 2027. The earliest realistic timeline for coverage expansion is 2028, and even that requires either TROA passage (unlikely) or significant price reductions through negotiation (possible).

Medicare patients should plan on the current coverage structure remaining in place for at least the next 24 months.

Decision tree: your actual options as a Medicare patient

Start here: Do you have type 2 diabetes (A1C ≥ 6.5% or prior diagnosis)?

→ Yes: Your provider can prescribe a GLP-1 (Ozempic, Mounjaro, Rybelsus) for diabetes management. Medicare Part D will cover it. Expect a specialty tier copay of $200 to $500 per month. You will likely lose weight as a secondary benefit. This is the covered pathway.

→ No diabetes: Continue below.

Are you enrolled in a Medicare Advantage plan (not original Medicare)?

→ Yes: Check your plan's Summary of Benefits or call member services. Ask: "Does my plan cover Wegovy or Zepbound as a supplemental benefit?" If yes, ask about prior authorization requirements and copay. If your plan covers it, submit a PA with your provider. If denied, continue below.

→ No, I have original Medicare Part D: Continue below.

Are you dual-eligible for Medicaid?

→ Yes: Check whether your state Medicaid program covers weight loss drugs (see the 14-state list above). If yes, ask your provider to submit a Medicaid prior authorization after Medicare denies coverage. If approved, you'll have $0 to low copay. If denied or your state doesn't cover, continue below.

→ No Medicaid: Continue below.

Can you afford $1,100+ per month for brand-name Wegovy or Zepbound?

→ Yes, and I prefer FDA-approved medications: Pay cash at a retail pharmacy. Use GoodRx to compare prices. Costco typically has the lowest cash price ($1,050 to $1,150). You will not be eligible for manufacturer savings cards.

→ No, that's not sustainable: Continue below.

Are you comfortable with compounded semaglutide or tirzepatide (not FDA-approved, lower cost)?

→ Yes: Consult with a telehealth platform (FormBlends: $179 to $349 per month) or a local compounding pharmacy. Compounded medications are prepared in response to an individual prescription, cost 75% to 85% less than brand-name, and require drawing doses from a vial.

→ No, I need an FDA-approved option: Your realistic options are limited. Consider enrolling in a clinical trial (some trials provide medication at no cost), waiting for policy changes, or exploring non-GLP-1 weight loss interventions (bariatric surgery is covered by Medicare with prior authorization for BMI ≥ 35).

FAQ

Does Medicare cover Ozempic for weight loss?

No. Medicare Part D covers Ozempic only when prescribed for type 2 diabetes. If your prescription lists weight loss or obesity as the primary indication, Medicare will deny coverage. The same active ingredient (semaglutide) is sold as Wegovy for weight loss, which Medicare also does not cover.

Does Medicare cover Wegovy?

Original Medicare Part D does not cover Wegovy. Some Medicare Advantage plans offer Wegovy coverage as a supplemental benefit, but fewer than 8% of MA plans included this coverage in 2025. Check your specific MA plan's formulary.

Does Medicare cover Mounjaro or Zepbound?

Medicare Part D covers Mounjaro when prescribed for type 2 diabetes. Medicare does not cover Zepbound (the same active ingredient, tirzepatide, approved for weight loss). The coverage rule is the same as for Ozempic and Wegovy: diabetes indication is covered, weight loss indication is not.

Can I use a manufacturer savings card for Wegovy if I have Medicare?

No. Federal law prohibits manufacturer copay assistance for Medicare, Medicaid, TRICARE, and VA patients. The Novo Nordisk savings card for Wegovy and the Eli Lilly savings card for Zepbound both exclude government program enrollees.

Will my Medicare Advantage plan cover weight loss injections?

Possibly, but unlikely. About 7.4% of Medicare Advantage plans offered some weight loss drug coverage in 2025. Check your plan's Summary of Benefits or formulary. If coverage is listed, expect prior authorization requirements and copays of $300 to $600 per month.

How much does Wegovy cost with Medicare?

If Medicare doesn't cover it (which is typical), you pay the full cash price: $1,100 to $1,400 per month at most retail pharmacies. Costco's cash price is usually $1,050 to $1,150. GoodRx coupons may reduce the price by $50 to $100.

What is the cheapest way to get weight loss injections on Medicare?

Compounded semaglutide or tirzepatide through a telehealth platform or compounding pharmacy. Prices range from $179 to $349 per month. Compounded medications are not FDA-approved but are prepared by state-licensed pharmacies and cost 75% to 85% less than brand-name drugs.

Does Medicaid cover weight loss injections if I'm dual-eligible?

It depends on your state. Fourteen states cover GLP-1s for weight loss under Medicaid as of April 2026, typically with prior authorization. If you're dual-eligible and live in a coverage state, Medicaid may cover the drug after Medicare denies it.

Can my doctor prescribe Ozempic off-label for weight loss and get Medicare to cover it?

No. Medicare's exclusion is indication-based. If the prescription's documented purpose is weight loss (even off-label use of a diabetes drug), Medicare will deny coverage. The exclusion applies to the use, not the molecule.

Will Medicare ever cover weight loss drugs?

Possibly, but not in the near term. The Treat and Reduce Obesity Act, which would remove the coverage exclusion, has been introduced in Congress repeatedly since 2012 but has never passed. The earliest realistic timeline for coverage expansion is 2028 or later, contingent on price negotiations or legislative changes.

What happens if I lose weight on Ozempic and my diabetes goes into remission?

Technically, if your diabetes resolves (A1C below 5.7% without medication), continued Ozempic is for weight maintenance, not diabetes treatment. Medicare coverage could be discontinued. In practice, enforcement is inconsistent, and many providers continue to document diabetes as the indication to maintain coverage.

Are there any weight loss medications Medicare does cover?

Medicare covers bariatric surgery for patients with BMI ≥ 35 and obesity-related comorbidities, which produces significant weight loss. Medicare also covers intensive behavioral therapy for obesity (up to 22 face-to-face sessions per year). Injectable weight loss medications remain excluded.

Sources

1. Social Security Act, Section 1860D-2(e)(2)(A), Medicare Prescription Drug Benefit exclusions. 2003.
2. Centers for Medicare & Medicaid Services. Medicare Part D coverage determination and appeals guidance. 2023.
3. Centers for Medicare & Medicaid Services. Primarily health-related supplemental benefits final rule. Federal Register. 2019.
4. Kaiser Family Foundation. Medicare Advantage supplemental benefits: coverage of obesity treatments. 2025.
5. Aimed Alliance. Prior authorization barriers for obesity medications in Medicare Advantage plans. 2024.
6. Congressional Budget Office. Cost estimate for the Treat and Reduce Obesity Act. 2023.
7. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021.
8. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022.
9. North Carolina Department of Health and Human Services. Medicaid coverage of anti-obesity medications policy update. 2024.
10. GoodRx Research. Cash prices for brand-name GLP-1 medications by pharmacy chain. 2026.
11. U.S. Department of Health and Human Services, Office of Inspector General. Anti-Kickback Statute and copay assistance programs. Advisory opinion 05-01. 2005.
12. Treat and Reduce Obesity Act, H.R. 1394 / S. 596, 118th Congress. 2025.
13. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on obesity. Endocr Pract. 2024.
14. National Council on Aging. State-by-state Medicaid coverage of obesity medications. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Saxenda, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Medicare and Medicaid are federal programs administered by the Centers for Medicare & Medicaid Services. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities.